P53 pathway changes and their influence on chronic lymphoproliferative diseases pathogenesis

The role of p53 family proteins, both in the pathogenesis of chronic lymphoproliferative disorders, and in aspects of the growi ng interest in the
therapeutic potential of so-called small molecules capable of influencing the regulatory "relationship" of p53, MDM2, p21 and P UMA is currently actively debated. The article is an attempt to summarize the data on experimental tumor and mouse models and availablen ithe l iterature results of studies using human lymphoid tumors. Prognostic significance of p53 family proteins expression in lymphoproliferativ e diseases and possible therapeutic approaches using the features of the p53 relationship with regulators and effectors genes are considered.